A phase 2 study of bevacizumab in combination with...

Lung Cancer 2015 / 02 Vol. 87; Iss. 2

A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109)

Hattori, Yoshihiro, Satouchi, Miyako, Shimada, Temiko, Urata, Yoshiko, Yoneda, Tsutomu, Mori, Masahide, Nishimura, Takashi, Sunadome, Hironobu, Kumagai, Toru, Imamura, Fumio, Fujita, Shiro, Kaji, Reik
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
87
Language:
english
Journal:
Lung Cancer
DOI:
10.1016/j.lungcan.2014.12.007
Date:
February, 2015
File:
PDF, 484 KB
english, 2015
Conversion to is in progress
Conversion to is failed